Navigation Links
Pradaxa Internal Bleeding Claims Are Now Being Reviewed by Resource4thePeople Attorneys

San Diego, CA (PRWEB) March 09, 2013

Resource4thePeople announced today that its attorneys are now investigating claims from victims who allegedly may have suffered serious health problems as a result of their use of the popular blood thinner Pradaxa.

“Our lawyers are now actively investigating these claims and stand ready to provide consultations in which the legal options available to seek compensation in such cases can be provided to consumers,” said Resource4thePeople.

“We are now reviewing these claims as a result of the increasing number of inquiries from consumers about their legal rights in connection with serious health side effects such as internal bleeding that may have occurred as a result of using the medication Pradaxa."

Resource4thePeople notes that the increasing number of Pradaxa lawsuits being filed has caused the federal court system to create what is called a multidistrict litigation* in which cases from across the country are being consolidated.

"We will be informing consumers about whether they may be eligible to join in this multidistrict litigation which is now under the supervision of a single judge in Illinois," said Resource4thePeople.

In such cases victims are allowed to file allegations through which they may seek compensation for wrongful deaths, medical costs, pain and suffering and other expenses if they can prove their claims.

Multidistrict litigations are so designated by the federal court system when a large number of cases involving similar allegations are brought under the supervision of a single judge for pre-trial evidence gathering and other legal procedures.

That judge may set bellwether trials, in which both plaintiffs' and defendants' lawyers test the strengths and weaknesses of their cases, and may also eventually designated the litigation as a massive class-action.

"One of the inquiries we are repeatedly receiving is whether it is to late to file a lawsuit that could be part of this multi-district litigation," said Resource4thePeople. "The answer, in the overwhelming number of cases, is no."

"The federal judge in the case has not issued any order prohibiting additional claims being filed and, in his most recent ruling, found that plaintiffs' lawyers will be granted access to documents they were seeking, which means there will still be additional time before any trial is held."

U.S. District Court Judge David R. Herndon granted the request to victims’ lawyers in the multidistrict litigation seeking access to a case settled by Pradaxa manufacturer Boehringer Ingelheim last year.

Judge Herndon’s ruling against Boehringer Ingelheim involved a $95 million settlement over the company’s marketing campaign to promote Pradaxa.

The current litigation before Herndon involves allegations that Pradaxa can cause serious internal bleeding problems which can lead to heart attacks and brain hemorrhages.*

Herndon has scheduled the first bellwether trials in the Pradaxa litigation to start in August, 2014.

Boehringer Ingelheim has denied the claims that have been filed against them in the Pradaxa litigation, including allegations that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.*

According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.

Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for warfarin but there is no antidote for Pradaxa and that in some cases deaths have occurred.

There are currently over 150 lawsuits in the multi-district litigation before Judge Herndon and Bloomberg News recently reported that Pradaxa “has been linked to more than 500 U.S. deaths over a two-year period.”**

Bloomberg also reported that “Concerns about Pradaxa’s safety surfaced soon after U.S. doctors began prescribing it. FDA officials said they received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.”**

Resource4thePeople also is advising consumers who may have been or are being treated with Pradaxa that the FDA recently issued a Drug Safety Communication warning that the medication should not be used in patients with mechanical prosthetic heart valves.***

In the communication the FDA also noted a previously released Drug Safety Communication about the risk of serious bleeding associated with the use of Pradaxa in patients with non-valvular atrial fibrillation, the population for which the drug is approved.


  • MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, U.S. District Court, Southern District of Illinois

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d’Oliveira & Associates Releases New Webpage on Pradaxa Lawsuits
2. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
3. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
4. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
5. DrugRisk Pradaxa Lawsuit Update: Court Denys Boehringer’s Protective Order Request
6. DrugRisk Update: Court Allows Charges of Prior Fraud Into Pradaxa Lawsuit
7. Bernstein Liebhard LLP Launches Pradaxa Lawsuit Website Providing Information on Mounting Pradaxa Litigation, Side Effects
8. Pradaxa Side Effect Problems Continue, as New Report Finds Pradaxa Bleeding More Likely to Result in Death, Bernstein Liebhard LLP Reports
9. 176 Pradaxa Lawsuits Now Pending in Federal Litigation, Discovery Well Underway, Bernstein Liebhard LLP Reports
10. DrugRisk Announces New Pradaxa Health Warning From Australia
11. Pradaxa Lawsuits Being Investigated by Bernstein Liebhard LLP, as Next Conference in Federal Pradaxa Litigation Set for January 10th
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... SAN ... today announced that the organization has awarded Education and Developmental Therapies (EDT), an ... Award. The award celebrates exceptional special needs providers that excel in synthesizing the ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies ... and population health arenas, is pleased to announce that VIP Care Services, a ... successfully implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case ...
(Date:12/1/2015)... Viejo, CA (PRWEB) , ... December 01, 2015 , ... ... length of footage, and with full control over customization, the possibilities are truly endless, ... frame rate, position randomization, overlay depth position, vertical flip, horizontal flip, depth of field ...
(Date:12/1/2015)... Chicago, IL (PRWEB) , ... December 01, 2015 ... ... the Unified Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This ... sell, deploy and support Cisco Unified Contact Center solutions targeted to the high-end ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... The Turks ... Journal, one of the leading digital news sites highlighting Caribbean destinations, has published five ... While much of North America shivers under chilly grey skies or worse, it's ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Assurex Health, Inc. today announced a ... providers an expanded range of options in helping ... depression, anxiety, bipolar disorder, posttraumatic stress disorder (PTSD), ... i .   --> i ... of two new drug classes, 17 FDA-approved medications ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... III clinical trials. 70% of new drugs registered in Europe ... in Russia . --> Russia has always ... 70% of new drugs registered in Europe in ... --> Russia has always been a ...
Breaking Medicine Technology: